IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
about
Recent advances in the molecular understanding of glioblastomaROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic StrategiesAdvances in the treatment of newly diagnosed glioblastomaMolecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateTreatment options and outcomes for glioblastoma in the elderly patientNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Glioblastoma genetics: in rapid flux.The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.TERT promoter mutations in primary and secondary glioblastomas.Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practiceDetermination of phosphate-activated glutaminase activity and its kinetics in mouse tissues using metabolic mapping (quantitative enzyme histochemistry)Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cellsMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationTERT promoter mutations and polymorphisms as prognostic factors in primary glioblastomaThe future role of personalized medicine in the treatment of glioblastoma multiformeEpidemiologic and molecular prognostic review of glioblastomaGenomic estimates of aneuploid content in glioblastoma multiforme and improved classificationThe global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for gliomaChromosome 7p11.2 (EGFR) variation influences glioma riskSurvival in glioblastoma: a review on the impact of treatment modalities.Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testingCharacterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study.IDH mutations: genotype-phenotype correlation and prognostic impact.Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolismThe combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Glioblastoma biomarkers from bench to bedside: advances and challenges.A radiosensitivity gene signature in predicting glioma prognostic via EMT pathwayDefective p53 antiangiogenic signaling in glioblastoma.
P2860
Q24632928-F3582868-B440-4A18-97BF-F0EB8A433804Q26747496-050E4532-D77E-47B3-908E-B5B12A073AFFQ26773514-DAACAF8D-B916-4FCF-AEEE-BB912FA1B077Q26785952-FFBBB303-5A6F-4C56-ACD6-805CEB3B7D0EQ26822717-A2D6840F-078A-4DCD-AB52-9C0546ECC74BQ26991605-4AC21C87-3893-427B-A1AA-3A0475C3C81EQ27687464-70B00CB5-AC45-4C71-ADAD-FE8E7016DC3FQ27691826-B0516DB5-D909-4C36-ACD5-4FDBB83126CCQ27851550-0482BC13-C85C-44EC-AA58-F3A69570EDA7Q27852506-40BAB4EB-51A0-4375-AC84-144B39E2AFBEQ28067399-1925B72E-F8E3-4529-AB0E-10DA27740258Q28083949-5B4CAE9A-7239-4D4B-9D12-B706DFE0B912Q28246788-32FC65E9-7DE2-4F8B-A5C1-E5B6A2A0B9D5Q28257733-ACC20513-2A22-4271-B550-B0B5BC4E07CEQ28383205-D987F3A0-570E-4FC3-8E48-EE114E6E83F7Q28390726-C3AC2918-907A-4751-9228-CA4A644E3D15Q28391635-F0C153AF-95A1-443C-8938-11E69B968F70Q28395302-DD6E1BC7-3036-4AD9-BC2E-E0E4725C5C9DQ28716240-92ECEC34-1E6A-40CD-A966-473637089DF0Q28741768-D6D71FFD-BAEF-4F92-9EC1-3EE19FBB2065Q28943530-97F6C8C0-2402-42F8-B126-64240C276254Q30251810-8EC51623-56D4-4831-96A2-BC289663F9BCQ30572884-A9E0454D-8D4B-4B00-8937-B01982CC1859Q30810936-06288109-3C1B-45B8-A4B0-9206CF709B19Q30937034-DDACA9DC-DCDF-4872-B8D4-82E75F4DAF5DQ33581974-CF3A699F-BD96-4944-BA78-887DAB83747DQ33611190-A9C98B0B-7156-4D7A-B013-834F88C5B464Q33615867-7C0B057E-AD3E-40F9-8328-F8EB71DDF306Q33616627-24538B13-45EB-42BF-846A-E6D8FEDDE56DQ33648875-8C7A737F-C3BB-461F-A5D3-27A85E66A30EQ33757037-4DCB21F8-0DD2-4926-8C6D-7A7AB2EF4FDDQ33782633-D89C75A8-1F06-4522-8E9B-4A8D2BC8BF48Q33804713-0BD9E636-45E4-455F-BB3C-99B84E3426FDQ33894486-F1DFF794-4383-478F-BCBE-8614077F7E18Q33923950-CDA68AD9-F0A5-437F-B34A-38077737E73AQ33965102-23DF05C6-E963-456A-B878-22D702176847Q34061985-D116A22B-979C-4059-8ED5-8D3ABB86EC60Q34103890-5DC562E8-177A-42C5-B803-8D9A7252CCB1Q34103984-17E8559C-6FE4-4525-B3BA-D9226DE4FE41Q34133118-A5413E0B-71CA-40AE-B32E-C4BDDE0AB3A5
P2860
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@en
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@nl
type
label
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@en
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@nl
prefLabel
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@en
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@nl
P2093
P1476
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
@en
P2093
Hiroko Ohgaki
Paul Kleihues
Sumihito Nobusawa
Takuya Watanabe
P304
P356
10.1158/1078-0432.CCR-09-0715
P407
P577
2009-09-15T00:00:00Z